Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Phase 1 Recruiting
234 enrolled
optINAVO
Phase 2 Recruiting
80 enrolled
OPERA-01
Phase 3 Recruiting
510 enrolled
SNV4818 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
320 enrolled
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/2 Recruiting
92 enrolled
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Phase 3 Recruiting
1,050 enrolled
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Phase 2 Recruiting
80 enrolled
OMAHA-015
Phase 2 Recruiting
250 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
ReDiscover-2
Phase 3 Recruiting
540 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
RaPhLRR
Phase 2 Recruiting
200 enrolled
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2 Recruiting
60 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
KOMODO-1
Phase 1 Recruiting
96 enrolled
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
Phase 2 Recruiting
37 enrolled
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1/2 Recruiting
205 enrolled
AVZO-023-1001
Phase 1/2 Recruiting
380 enrolled
reaINAVO
Recruiting
500 enrolled
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2 Recruiting
484 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 Recruiting
28 enrolled
ELAINEIII
Phase 3 Recruiting
500 enrolled
Dauntless-1
Phase 1/2 Recruiting
61 enrolled
GERTRUDE
Phase 2 Recruiting
135 enrolled
CAPItrue
Phase 3 Recruiting
300 enrolled
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
25 enrolled
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1/2 Recruiting
280 enrolled
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
260 enrolled
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Phase 3 Recruiting
312 enrolled
LITESPARK-029
Phase 2 Recruiting
120 enrolled
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Phase 1/2 Recruiting
49 enrolled
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Phase 2 Recruiting
20 enrolled
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Phase 2 Recruiting
15 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
ITHRAN
Phase 2 Recruiting
123 enrolled
VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/2 Recruiting
63 enrolled
DARE
Phase 2 Recruiting
70 enrolled
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Phase 3 Recruiting
460 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 Recruiting
256 enrolled
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2 Recruiting
39 enrolled
PIKture-01
Phase 1 Recruiting
200 enrolled
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Phase 2 Recruiting
31 enrolled